1. Home
  2. ALT vs CELC Comparison

ALT vs CELC Comparison

Compare ALT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • CELC
  • Stock Information
  • Founded
  • ALT 1997
  • CELC 2011
  • Country
  • ALT United States
  • CELC United States
  • Employees
  • ALT N/A
  • CELC N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • CELC Medical Specialities
  • Sector
  • ALT Health Care
  • CELC Health Care
  • Exchange
  • ALT Nasdaq
  • CELC Nasdaq
  • Market Cap
  • ALT 397.4M
  • CELC 440.0M
  • IPO Year
  • ALT N/A
  • CELC 2017
  • Fundamental
  • Price
  • ALT $4.19
  • CELC $13.63
  • Analyst Decision
  • ALT Strong Buy
  • CELC Strong Buy
  • Analyst Count
  • ALT 6
  • CELC 6
  • Target Price
  • ALT $18.20
  • CELC $30.67
  • AVG Volume (30 Days)
  • ALT 11.7M
  • CELC 206.7K
  • Earning Date
  • ALT 08-07-2025
  • CELC 08-13-2025
  • Dividend Yield
  • ALT N/A
  • CELC N/A
  • EPS Growth
  • ALT N/A
  • CELC N/A
  • EPS
  • ALT N/A
  • CELC N/A
  • Revenue
  • ALT $20,000.00
  • CELC N/A
  • Revenue This Year
  • ALT N/A
  • CELC N/A
  • Revenue Next Year
  • ALT $1,557,547.90
  • CELC N/A
  • P/E Ratio
  • ALT N/A
  • CELC N/A
  • Revenue Growth
  • ALT N/A
  • CELC N/A
  • 52 Week Low
  • ALT $2.90
  • CELC $7.58
  • 52 Week High
  • ALT $11.16
  • CELC $19.77
  • Technical
  • Relative Strength Index (RSI)
  • ALT 39.67
  • CELC 62.38
  • Support Level
  • ALT $4.33
  • CELC $12.48
  • Resistance Level
  • ALT $4.79
  • CELC $14.19
  • Average True Range (ATR)
  • ALT 0.52
  • CELC 0.75
  • MACD
  • ALT -0.16
  • CELC 0.07
  • Stochastic Oscillator
  • ALT 26.92
  • CELC 80.73

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: